Minding The Middle: FDA Fleshes Out De Novo Regs As The Program Expands
Executive Summary
A new proposed rule on the de novo classification process does not advance any major policy reforms, but its release underscores the growing popularity of the regulatory pathway that provides flexibility for US FDA and industry in the space between 510(k)s and PMAs.
You may also be interested in...
FDA Finalizes De Novo Process, Updates Related Guidance Docs
The pathway is used to clear class I and II products that don’t have a predicate device, including many innovative technologies. The original draft rule came out in 2018.
FDA Gives Insight On Changing Approval Landscape
Device center officials at the US agency focused on new approval pathways at RAPS Convergence 2020.
FDA Action-Item List Shows Plans To Revamp De Novo, Combo Product, QSR Regs, And More
Planned US FDA actions on the spring 2020 Agency Rule List show expected rules around de novo applications, and combination product classification and appeals – as well as the long-awaited Quality System Regulation overhaul.